Figure 1: Model of adjuvant chemotherapy effectiveness in therapeutic approaches with similar chemotherapy protocols used based only on common prognostic-predictive parameters without assessment of individual gene profile of carcinomas. (All patients belong to the same risk group of disease, have similar histologic features, stage of the disease and adjuvant chemotherapy protocol used. However, the true benefit – Responders without side effect accounts only for 25%. Fifty% of patients does not benefit from chemotherapy selected on the results from common PPP).